Cargando…

Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study

BACKGROUND: The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people with lower socioeconomic status (SES); however, it is u...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Beini, Chang, Alex R., Inker, Lesley A., Selvin, Elizabeth, Grams, Morgan E., Shin, Jung-Im
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348594/
https://www.ncbi.nlm.nih.gov/pubmed/35928911
http://dx.doi.org/10.1016/j.lana.2022.100249
_version_ 1784761948589522944
author Lyu, Beini
Chang, Alex R.
Inker, Lesley A.
Selvin, Elizabeth
Grams, Morgan E.
Shin, Jung-Im
author_facet Lyu, Beini
Chang, Alex R.
Inker, Lesley A.
Selvin, Elizabeth
Grams, Morgan E.
Shin, Jung-Im
author_sort Lyu, Beini
collection PubMed
description BACKGROUND: The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people with lower socioeconomic status (SES); however, it is unknown whether the use of obesogenic medications differs by SES. METHODS: We included adults with overweight or obesity and used prescription medications from 2009-2018 of the US National Health and Nutrition Examination Survey. We examined the associations between a composite measure of SES and use of obesogenic medications and anti-obesity medications. The composite SES included <high school education (1 point), household income below federal poverty level (1 point), no insurance (2 points), and public health insurance only (1 point). We defined 3 composite SES groups (0 [high], 1 [intermediate], and ≥2 points [low]). FINDINGS: Among 10,673 US adults with overweight or obesity, 20.0% had low SES. Use of obesogenic medications was common (37.7%). Low (vs. high) SES was associated with greater obesogenic medication use, independent of demographic characteristics, prescription medication burden, and comorbidities (OR 1.3 [1.2-1.5]). Among 12,133 eligible participants, utilization of anti-obesity medications was very low overall (0.5%) and within all SES groups (low 0.27%, intermediate 0.71, and high 0.65%). INTERPRETATION: Our findings highlight common and modifiable risk factors for obesity. Clinicians should screen patient medications for those that may cause weight gain and increase adoption of anti-obesity medications, especially among adults living in low SES. FUNDING: The National Institute of Diabetes and Digestive and Kidney Disease (R01DK115534, K24HL155861, and K01DK121825).
format Online
Article
Text
id pubmed-9348594
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93485942022-08-03 Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study Lyu, Beini Chang, Alex R. Inker, Lesley A. Selvin, Elizabeth Grams, Morgan E. Shin, Jung-Im Lancet Reg Health Am Articles BACKGROUND: The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people with lower socioeconomic status (SES); however, it is unknown whether the use of obesogenic medications differs by SES. METHODS: We included adults with overweight or obesity and used prescription medications from 2009-2018 of the US National Health and Nutrition Examination Survey. We examined the associations between a composite measure of SES and use of obesogenic medications and anti-obesity medications. The composite SES included <high school education (1 point), household income below federal poverty level (1 point), no insurance (2 points), and public health insurance only (1 point). We defined 3 composite SES groups (0 [high], 1 [intermediate], and ≥2 points [low]). FINDINGS: Among 10,673 US adults with overweight or obesity, 20.0% had low SES. Use of obesogenic medications was common (37.7%). Low (vs. high) SES was associated with greater obesogenic medication use, independent of demographic characteristics, prescription medication burden, and comorbidities (OR 1.3 [1.2-1.5]). Among 12,133 eligible participants, utilization of anti-obesity medications was very low overall (0.5%) and within all SES groups (low 0.27%, intermediate 0.71, and high 0.65%). INTERPRETATION: Our findings highlight common and modifiable risk factors for obesity. Clinicians should screen patient medications for those that may cause weight gain and increase adoption of anti-obesity medications, especially among adults living in low SES. FUNDING: The National Institute of Diabetes and Digestive and Kidney Disease (R01DK115534, K24HL155861, and K01DK121825). Elsevier 2022-04-02 /pmc/articles/PMC9348594/ /pubmed/35928911 http://dx.doi.org/10.1016/j.lana.2022.100249 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Lyu, Beini
Chang, Alex R.
Inker, Lesley A.
Selvin, Elizabeth
Grams, Morgan E.
Shin, Jung-Im
Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study
title Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study
title_full Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study
title_fullStr Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study
title_full_unstemmed Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study
title_short Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study
title_sort socioeconomic status and use of obesogenic and anti-obesity medications in the united states: a population-based study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348594/
https://www.ncbi.nlm.nih.gov/pubmed/35928911
http://dx.doi.org/10.1016/j.lana.2022.100249
work_keys_str_mv AT lyubeini socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy
AT changalexr socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy
AT inkerlesleya socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy
AT selvinelizabeth socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy
AT gramsmorgane socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy
AT shinjungim socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy